Format

Send to:

Choose Destination
See comment in PubMed Commons below
Exp Biol Med (Maywood). 2008 Aug;233(8):968-79. doi: 10.3181/0802-RM-58. Epub 2008 May 14.

Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function.

Author information

  • 1Department of Neural and Behavioral Sciences, H109, The M.S. Hershey Medical Center, 500 University Drive, Rm. C3729, Hershey, PA 17033, USA. isz1@psu.edu

Abstract

The imidazoquinoline compounds imiquimod and resiquimod are low-molecular-weight immune response modifiers that have potent anti-viral and anti-tumor properties. The mechanism by which they exert their effects remains unclear. Using pancreatic and colorectal cancer cells, as well as squamous carcinoma cells of the head and neck in tissue culture, which eliminated the immune system and toll-like receptors, we show that the imidazoquinolines upregulate the Opioid Growth Factor receptor (OGFr), which in turn stimulates the interaction of the OGF-OGFr axis. This native, tonically active inhibitory pathway regulates cell proliferation by modulating cyclin dependent kinase inhibitors, resulting in a retardation of cells at the G(1)-S interface of the cell cycle. Neutralization of OGF or knockdown of OGFr by siRNA technology eliminates the inhibitory effects of imidazoquinolines on cell replication. This exciting new knowledge of the mechanism of imidazoquinolines has important physiological relevance, and allows strategies to be developed for the use of these agents that will enhance effectiveness as well as attenuate side-effects.

PMID:
18480416
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk